RSV healthcare burden in adults before and since the emergence of the COVID-19 pandemic in 6 European countries
Preprint
Abstract
Introduction: Respiratory Syncytial Virus (RSV) is a major cause of morbidity in older adults. With the emergence of the coronavirus disease 2019 (COVID-19) and the subsequent changes in respiratory viral circulation, it is crucial to reassess RSV-associated healthcare burden in adults. This study assessed RSV-associated healthcare burden in adults in six European countries before and during the COVID-19 pandemic. Methods: We conducted a retrospective analysis using national hospital admissions data from Denmark, England, Finland, the Netherlands, Scotland, and regional surveillance data from the Valencia region (Spain). We included patients aged ≥18 years hospitalised for respiratory tract infections (RTIs) from 2016 to 2023. We assessed RSV-coded and laboratory-confirmed hospitalisations, intensive care unit (ICU) admissions, in-hospital length of stay (LOS), and mortality. Results: RSV-associated hospitalisations significantly reduced during the 2020/2021 season across all countries, coinciding with strict COVID-19 preventive measures, but resurged in subsequent seasons. We observed the highest hospitalisation rates in adults aged ≥85 years. RSV-coded hospitalisations were found to underestimate the true burden when compared with laboratory-confirmed cases. Underestimation factors ranged from 1.1 to 4.3 times across countries. No significant differences were observed in LOS or ICU admission rates for RSV-associated hospitalisations compared to RTIs. Discussion: Our findings underscore the complex epidemiology of RSV in older adults. The differences between RSV-coded and laboratory-confirmed cases highlight the critical need for improved surveillance and diagnostic practices to better assess the true burden. Our findings could be vital for guiding public health strategies, particularly with the recent introduction of RSV vaccines for older adults.Keywords
This publication has 33 references indexed in Scilit:
- Increased Pediatric Respiratory Syncytial Virus Case Counts Following the Emergence of SARS-CoV-2 Can Be Attributed to Changes in TestingClinical Infectious Diseases, 2024
- Why has the epidemiology of RSV changed during the COVID-19 pandemic?eClinicalMedicine, 2023
- RSV vaccines score landmark FDA approvalsNature Reviews Drug Discovery, 2023
- Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling StudyInfectious Diseases and Therapy, 2023
- Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemicJournal of Medical Virology, 2021
- COVID-19 public health measures and respiratory syncytial virusThe Lancet Child & Adolescent Health, 2020
- Coronavirus Disease 2019 Pandemic: Impact Caused by School Closure and National Lockdown on Pediatric Visits and Admissions for Viral and Nonviral Infections—a Time Series AnalysisClinical Infectious Diseases, 2020
- What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections?Journal of Clinical Virology, 2019
- Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System laboratories, United States, 2016Journal of Clinical Virology, 2018
- Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illnessJournal of Clinical Virology, 2006